poisar

Stocks · News reference

Rezolute Updates Investors on Ersodetug Programs and Financial Position

Fiscal.ai

Rezolute released an investor presentation detailing its clinical progress for ersodetug, including a cash runway extending through Q1 2028 and updates on its hyperinsulinism programs.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Rezolute, Inc. (RZLT)

    Filed: 2026-11-16 AccNo: 0001104659-26-127490 Size: 607 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits